At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KURE KraneShares MSCI All China Health Care Index ETF
Pre-Mkt 07-14 07:15:49 EDT
16.86
-0.13
-0.75%
盘前16.80
-0.06-0.36%
07:00 EDT
High16.96Low16.80Vol5.45K
Open16.91D1 Closing16.99Amplitude0.94%
Mkt Cap79.22MTradable Cap79.22MTotal Shares4.70M
T/O91.98KT/O Rate0.12%Tradable Shares4.70M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CSPC Says China Regulator Grants Breakthrough Therapy Designation for Her2-positive Breast Cancer Combo
Reuters  ·  15 minutes ago
CSPC Says China Regulator Grants Breakthrough Therapy Designation for Her2-positive Breast Cancer Combo
CSPC Pharmaceutical - Docetaxel (albumin-bound) and Anbenitamab Granted Breakthrough Therapy Designation in China
THOMSON REUTERS  ·  16 minutes ago
CSPC Pharmaceutical - Docetaxel (albumin-bound) and Anbenitamab Granted Breakthrough Therapy Designation in China
Spero Licenses Innovent's Experimental Immune Disease Drug for up to $1.1 Billion
Reuters  ·  33 minutes ago
Spero Licenses Innovent's Experimental Immune Disease Drug for up to $1.1 Billion
Innovent Biologics Licenses Anti-cd40l Antibody Ibi355 to Spero in Deal Worth About USD 1.1 Billion
Reuters  ·  18:01
Innovent Biologics Licenses Anti-cd40l Antibody Ibi355 to Spero in Deal Worth About USD 1.1 Billion
Spero Therapeutics - Innovent to Receive Payments Totaling About $1.1 Bln Plus Tiered Royalties
THOMSON REUTERS  ·  18:00
Spero Therapeutics - Innovent to Receive Payments Totaling About $1.1 Bln Plus Tiered Royalties
Spero Therapeutics - Innovent to Initiate Phase 2 Trial for Sjögren’s Disease in China by Early 2027
THOMSON REUTERS  ·  18:00
Spero Therapeutics - Innovent to Initiate Phase 2 Trial for Sjögren’s Disease in China by Early 2027
Spero Therapeutics - to Initiate Phase 2 Trial for SP001 in Igg4-rd in Q2 2027
THOMSON REUTERS  ·  18:00
Spero Therapeutics - to Initiate Phase 2 Trial for SP001 in Igg4-rd in Q2 2027
Innovent Biologics - Spero Receives Exclusive Global Rights to Ibi355 Excluding Greater China
THOMSON REUTERS  ·  18:00
Innovent Biologics - Spero Receives Exclusive Global Rights to Ibi355 Excluding Greater China
Innovent Biologics and Spero Therapeutics Announce Exclusive License for Ibi355 (sp001), a Phase 2-ready Third-generation Anti-cd40l Antibody
THOMSON REUTERS  ·  18:00
Innovent Biologics and Spero Therapeutics Announce Exclusive License for Ibi355 (sp001), a Phase 2-ready Third-generation Anti-cd40l Antibody
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
GlobeNewswire  ·  18:00
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Akeso Launches US Phase II Trial of Cadonilimab Combination in Perioperative Gastric Cancer
Reuters  ·  16:19
Akeso Launches US Phase II Trial of Cadonilimab Combination in Perioperative Gastric Cancer
Phase Ii Trial of Cadonilimab(pd-1/ctla-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer
THOMSON REUTERS  ·  16:18
Phase Ii Trial of Cadonilimab(pd-1/ctla-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer
Wuxi Biologics (cayman) Stock Falls 1.7% in Hong Kong
Dow Jones  ·  07-13 16:32
Wuxi Biologics (cayman) Stock Falls 1.7% in Hong Kong
CSPC Pharma Secures $25 Million R&D Milestone Payment from AstraZeneca Under Strategic Collaboration
Deep News  ·  07-12 16:00
CSPC Pharma Secures $25 Million R&D Milestone Payment from AstraZeneca Under Strategic Collaboration
Is Innovent Biologics (SEHK:1801) Undervalued After Securing China Rights To Verzenios?
Simply Wall St.  ·  07-12 09:35
Is Innovent Biologics (SEHK:1801) Undervalued After Securing China Rights To Verzenios?
WuXi Biologics (Cayman) (SEHK:2269) Wins FDA Inspection As Its Undervalued Case Builds
Simply Wall St.  ·  07-12 03:20
WuXi Biologics (Cayman) (SEHK:2269) Wins FDA Inspection As Its Undervalued Case Builds
CSPC Pharma Receives $25 Million R&D Milestone Payment from AstraZeneca Under Strategic Collaboration and Licensing Deal
Stock News  ·  07-10
CSPC Pharma Receives $25 Million R&D Milestone Payment from AstraZeneca Under Strategic Collaboration and Licensing Deal
CSPC Pharma Receives USD 25 Million R&D Milestone Payment from Astrazeneca Under Collaboration Deal
Reuters  ·  07-10
CSPC Pharma Receives USD 25 Million R&D Milestone Payment from Astrazeneca Under Collaboration Deal
TOT Biopharm Schedules Board Meeting to Review Interim Results
Reuters  ·  07-10
TOT Biopharm Schedules Board Meeting to Review Interim Results
Wuxi XDC Schedules Board Meeting to Review Interim Results
Reuters  ·  07-10
Wuxi XDC Schedules Board Meeting to Review Interim Results

Introduction

Company Name.
KraneShares MSCI All China Health Care Index ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in instruments in its underlying index or in instruments that have economic characteristics similar to those in the underlying index. The underlying index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint, which is designed to measure the equity market performance of Chinese companies in the healthcare sector. The fund is non-diversified.
Issue price:
--